European Patent Convention

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024
Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Clinical Trials, Artificial intelligence, Central nervous system disease, Pain, IGC, Loss, GMP, Composition, Treating, Cannabinoid, University, PPE, Certification, Administration, Patent, Patient, CBD, THC, LMP, Agitation, American University, Dementia, Bank statement, Somatic symptom disorder, Human, European Patent Convention, Pharmaceutical industry

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Merck, Kidney, USD, POC, Adrenoleukodystrophy, Merck Serono, EPO, JPY, AMN, Sumitomo Pharma, European Patent Convention, Safety, Biomarker, EUR, ALD, ADPKD, Serono, Adenosine, Pharmacokinetics, Patent, Fatty liver disease, Patient, Diabetes, Disease, NASH, Plasma, Male, DSM-IV codes, VLCFA, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

NaturalShrimp, Inc. Files International Patent Applications

Retrieved on: 
Thursday, February 15, 2024
OTCQB, Aquaculture, Philosophy, NOS, File, Seafood, Growth, ESG, RAS, Patent, EPC, United States patent law, Intellectual property, IP, Lawyer, Child, European Patent Convention, Domestication

DALLAS, Feb. 15, 2024 /PRNewswire/ -- NaturalShrimp Incorporated (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), is pleased to announce the successful filing of patents in Japan, Thailand, and Australia. These filings mark a significant step in our commitment to advancing sustainable aquaculture practices and ensuring the future of global seafood production.

Key Points: 
  • These filings mark a significant step in our commitment to advancing sustainable aquaculture practices and ensuring the future of global seafood production.
  • The intellectual property rights represented by the Company's previously issued patents constitute the backbone of NaturalShrimp's business.
  • In this respect, NaturalShrimp has already filed for patent protection in Japan, Thailand, Australia, and the European Patent Convention (EPC), all areas in which the Company is either currently doing business or in which the Company seeks to do business.
  • Patent protection is a very costly process and this extended time period allows the Company to methodically plan and still act with financial responsibility.

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Temperature, NDRA, Cryotherapy, Integration, European Patent Convention, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.
  • ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.
  • These patents protect novel innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures and thermal ablation.
  • "We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a robust portfolio that now encompasses 74 granted patents."

MaxVal Unveils Insights into Global Innovation Landscape with the Release of 2023 Patent Publication Trends Report

Retrieved on: 
Wednesday, February 14, 2024
LOS, IBM, EPO, Growth, Samsung, Qualcomm, Apple, United States patent law, Publication, European Patent Convention

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- MaxVal Group, Inc. ("MaxVal"), a leading provider of intellectual property management solutions, announced today the release of its highly anticipated 2023 Patent Publication Trends Report.

Key Points: 
  • LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- MaxVal Group, Inc. ("MaxVal"), a leading provider of intellectual property management solutions, announced today the release of its highly anticipated 2023 Patent Publication Trends Report.
  • The comprehensive report provides invaluable insights into the ever-evolving landscape of patent publications, highlighting key trends and notable developments.
  • US Innovation Powerhouse: Despite global shifts, leading US-based companies like Qualcomm, IBM, and Apple maintain their status among the top 30 filers, showcasing continued innovation and competitiveness.
  • MaxVal's 2023 Patent Publication Trends Report is a valuable resource for intellectual property professionals, researchers, and policymakers seeking a deeper understanding of the global patent landscape.

Lathrop GPM Adds 8 Member Veteran IP High Tech, Electrical and Mechanical Engineering Team to Dallas

Retrieved on: 
Tuesday, February 6, 2024
File, Growth, Patent, University, Electronics, Internal Revenue Service, Baylor University, Southern Methodist University, Intellectual property, European Patent Convention, Viceroy, Average revenue per user, Apple Inc., Federal Reserve Bank, City, IP, Methodist University, Garrison, Culture, Software, Engineering, Industrial design

DALLAS, Feb. 6, 2024 /PRNewswire-PRWeb/ -- Lathrop GPM LLP is proud to announce the addition of eight IP professionals to its Intellectual Property practice group in Dallas. Robert Lord joins as a partner along with attorneys Annemarie Vicere, Ted Fay and Ben King. In addition, Roxana Malladi joins as a patent agent, Jaime Hathaway joins as a paralegal, Kate Ohale joins as a foreign filing specialist, and Hannah Ochoa as an IP docketing specialist. All eight come from Ferguson Braswell Fraser Kubasta PC. The expansion of the IP team in Dallas came just a week following growth in the Denver and Kansas City offices.

Key Points: 
  • DALLAS, Feb. 6, 2024 /PRNewswire-PRWeb/ -- Lathrop GPM LLP is proud to announce the addition of eight IP professionals to its Intellectual Property practice group in Dallas.
  • The expansion of the IP team in Dallas came just a week following growth in the Denver and Kansas City offices.
  • Lathrop GPM Managing Partner Cameron Garrison said, "This team of exceptional patent attorneys are well-known in the high tech and engineering industry and have strong ties to both Texas and California markets.
  • We look forward to working with them on the continued development of our high tech, electrical and mechanical engineering practice."

Iridex Corporation Receives European Patent on MicroPulse Technology

Retrieved on: 
Tuesday, February 6, 2024
Paratriathlon, Commitment, Glaucoma, Ophthalmology, Safety, European Patent Convention, Unified Patent Court, Laser, IRIX, Retina, Unitary patent, Risk, Medical imaging

This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments.

Key Points: 
  • This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments.
  • Iridex is the exclusive provider of MicroPulse® devices that utilize the patented technology.
  • In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.
  • A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.

Envoy Medical Announces Three Additional Patents for Implantable Cochlear Systems

Retrieved on: 
Monday, January 22, 2024
European Patent Convention, Patient, Lead, Hearing loss, United States patent law, Patent, BEAR, Hearing, Medical device

WHITE BEAR LAKE, Minnesota, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it recently has been awarded three additional patents. These patents are further evidence of Envoy Medical’s determination to be an innovation leader in hearing health to benefit patients with significant hearing loss.  The patents are as follows:

Key Points: 
  • WHITE BEAR LAKE, Minnesota, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it recently has been awarded three additional patents.
  • These patents are further evidence of Envoy Medical’s determination to be an innovation leader in hearing health to benefit patients with significant hearing loss.
  • The patents are as follows:
    The US Patent & Trademark Office issued Envoy Medical Corporation US Pat.
  • We believe our system’s design will allow us an opportunity to separate ourselves from others and provide patients with a new hearing option.”

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Retrieved on: 
Thursday, January 18, 2024
DSM-IV codes, European Patent Convention, Patient, EPO, IP, Psychiatry, Communication, TRD, MDD, Patent, Research, GHRS, Pharmaceutical industry

It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.

Key Points: 
  • It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.
  • Theis Terwey, CEO and Co-founder of GH Research said: “We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments.
  • Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP.
  • We feel well placed to progress the rest of our patent portfolio through the examination process in Europe, the US and beyond, and are looking forward to exploring additional opportunities with mebufotenin through continuous research and development.”

LiquidText Launches Law School Campus Site License Program

Retrieved on: 
Monday, January 29, 2024
Student, European Patent Convention, Faculty, Participation, Microsoft, Partnership, Lawyer, Knowledge, University, High courts of India, Law library, Supreme court, Apple, College, Nursing

NEW YORK, Jan. 29, 2024 /PRNewswire/ -- LiquidText, the award-winning reading, note-taking, and document analysis platform, the only productivity app to win Editor's Choice from BOTH Apple AND Microsoft, today launched its Law Campus Site License Program. This program makes LiquidText available at a deeply discounted price which is affordable by academic institutions of any size, enabling all students, faculty and staff access to all the advanced features of LiquidText as part of their Campus Digital Experience.

Key Points: 
  • This program makes LiquidText available at a deeply discounted price which is affordable by academic institutions of any size, enabling all students, faculty and staff access to all the advanced features of LiquidText as part of their Campus Digital Experience.
  • Our new Campus Wide Program demonstrates LiquidText's ongoing commitment to the academic channel, along with our existing aggressive student discounts and free edition, our Campus Site License Program represents our attempt to remove any economic barrier for students to gain full access to our Technology."
  • LiquidText is pleased to announce that the University of Oklahoma College of Law has become the first academic institution to participate, enabling its entire 600+ member campus population with LiquidText.
  • As the only Apple Distinguished Law School in North America, OU Law stands at the forefront of technological innovation in legal education.